

- Howlander N, Noone AM, Krapcho M, et al, eds. *SEER Cancer Statistics Review, 1975–2008*. Bethesda, MD: National Cancer Institute; 2011.
- Bennett RL, French KS, Resta RG, et al. Standardized human pedigree nomenclature: Update and assessment of the recommendations of the National Society of Genetic Counselors. *J Genet Couns* 2008;17:424–433.
- Bennett RL, Steinhaus KA, Ulrich SB, et al. Recommendations for standardized human pedigree nomenclature. Pedigree Standardization Task Force of the National Society of Genetic Counselors. *Am J Hum Genet* 1995;56:745–752.
- Love RR, Evans AM, Josten DM. The accuracy of patient reports of a family history of cancer. *J Chronic Dis* 1985;38:289–293.
- Theis B, Boyd N, Lockwood G, et al. Accuracy of family cancer history in breast cancer patients. *Eur J Cancer Prev* 1994;3:321–327.
- Reid GT, Walter FM, Brisbane JM, et al. Family history questionnaires designed for clinical use: a systematic review. *Public Health Genomics* 2009;12:73–83.
- Jefferies S, Goldgar D, Eeles R. The accuracy of cancer diagnoses as reported in families with head and neck cancer: A case-control study. *Clin Oncol (R Coll Radiol)* 2008;20:309–314.
- Murff HJ, Spigel DR, Syngal S. Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. *JAMA* 2004;292:1480–1489.
- Chang ET, Smedby KE, Hjalgrim H, et al. Reliability of self-reported family history of cancer in a large case-control study of lymphoma. *J Natl Cancer Inst* 2006;98:61–68.
- Ziogas A, Horick NK, Kinney AY, et al. Clinically relevant changes in family history of cancer over time. *JAMA* 2011;306:172–178.
- Walsh T, Casadei S, Coats KH, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. *JAMA* 2006;295:1379–1388.
- Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. *Am J Hum Genet* 1998;62:676–689.
- Frank TS, Manley SA, Olopade OI, et al. Sequence analysis of BRCA1 and BRCA2: Correlation of mutations with family history and ovarian cancer risk. *J Clin Oncol* 1998;16:2417–2425.
- Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. *Science* 1994;266:66–71.
- Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. *Nature* 1995;378:789–792.
- Struwing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. *N Engl J Med* 1997;336:1401–1408.
- Kauff ND, Perez-Segura P, Robson ME, et al. Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. *J Med Genet* 2002;39:611–614.
- Thorlacius S, Olafsdottir G, Tryggvadottir L, et al. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. *Nat Genet* 1996;13:117–119.
- Unger MA, Nathanson KL, Calzone K, et al. Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. *Am J Hum Genet* 2000;67:841–850.
- Chappuis PO, Nethercot V, Foulkes WD. Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. *Semin Surg Oncol* 2000;18:287–295.
- Phillips KA, Andrulis IL, Goodwin PJ. Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: Are they prognostically different? *J Clin Oncol* 1999;17:3653–3663.
- Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: A critical review. *J Clin Oncol* 2008;26:2568–2581.
- Boyd J, Sonoda Y, Federici MC, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. *JAMA* 2000;283:2260–2265.
- Lakhani SR, Manek S, Penault-Llorca F, et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. *Clin Cancer Res* 2004;10:2473–2481.
- Levine DA, Argenta PA, Yee CJ, et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. *J Clin Oncol* 2003;21:4222–4227.
- Cass J, Baldwin RL, Varkey T, et al. Improved survival in women with BRCA-associated ovarian carcinoma. *Cancer* 2003;97:2187–2195.
- Arun B, Bayraktar S, Liu DD, et al. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: A single-institution experience. *J Clin Oncol* 2011;29:3739–3746.
- Berry DA, Iversen ES Jr, Gudbjartsson DF, et al. BRCAPro validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. *J Clin Oncol* 2002;20:2701–2712.
- Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. *Stat Med* 2004;23:1111–1130.
- Couch FJ, DeShano ML, Blackwood MA, et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. *N Engl J Med* 1997;336:1409–1415.
- Shattuck-Eidens D, Oliphant A, McClure M, et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. *JAMA* 1997;278:1242–1250.
- Kang HH, Williams R, Leary J, et al. Evaluation of models to predict BRCA germline mutations. *Br J Cancer* 2006;95:914–920.
- Barcenas CH, Hosain GM, Arun B, et al. Assessing BRCA carrier probabilities in extended families. *J Clin Oncol* 2006;24:354–360.
- James PA, Doherty R, Harris M, et al. Optimal selection of individuals for BRCA mutation testing: A comparison of available methods. *J Clin Oncol* 2006;24:707–715.
- Saslow D, Castle PE, Cox JT, et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. *CA Cancer J Clin* 2007;57:7–28.
- King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. *Science* 2003;302:643–646.
- Ozcelik H, Schmocker B, Di Nicola N, et al. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. *Nat Genet* 1997;16:17–18.
- Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. *Am J Hum Genet* 2003;72:1117–1130.
- Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. *Am J Hum Genet* 2001;68:700–710.
- The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. *J Natl Cancer Inst* 1999;91:1310–1316.
- Thompson D, Easton DF. Cancer incidence in BRCA1 mutation carriers. *J Natl Cancer Inst* 2002;94:1358–1365.
- Thompson D, Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. *Am J Hum Genet* 2001;68:410–419.
- van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, et al. Cancer risks in BRCA2 families: Estimates for sites other than breast and ovary. *J Med Genet* 2005;42:711–719.
- Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. *J Natl Cancer Inst* 2001;93:1633–1637.
- Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. *J Clin Oncol* 2004;22:1055–1062.
- Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. *N Engl J Med* 2001;345:159–164.
- Robson M, Svahn T, McCormick B, et al. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: A clinic-based series. *Cancer* 2005;103:44–51.
- Narod SA, Brunet JS, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. *Lancet* 2000;356:1876–1881.
- Gronwald J, Tung N, Foulkes WD, et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. *Int J Cancer* 2006;118:2281–2284.
- Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. *N Engl J Med* 2002;346:1609–1615.
- Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. *N Engl J Med* 2002;346:1616–1622.
- Piver MS, Jishi MF, Tsukada Y, et al. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. *Cancer* 1993;71:2751–2755.
- Modan B, Hartge P, Hirsh-Yechezkel G, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. *N Engl J Med* 2001;345:235–240.
- Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. *N Engl J Med* 1998;339:424–428.
- Narod SA, Dubé MP, Kihl J, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. *J Natl Cancer Inst* 2002;94:1773–1779.
- Daly MB, Pilarski R, Axilbund JE, et al. *NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Genetic/Familial High-Risk Assessment: Breast and Ovarian V1.2014*. © 2014 National Comprehensive Cancer Network, Inc. www.nccn.org. Accessed September 18, 2014.
- Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: A review of the literature. *J Clin Oncol* 2004;22:735–742.
- DiCastro M, Frydman M, Friedman I, et al. Genetic counseling in hereditary breast/ovarian cancer in Israel: Psychosocial impact and retention of genetic information. *Am J Med Genet* 2002;111:147–151.

59. Lodder LN, Frets PG, Trisburg RW, et al. One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: Emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). *Breast Cancer Res Treat* 2002;73:97–112.
60. Crotser CB, Boehmke M. Survivorship considerations in adults with hereditary breast and ovarian cancer syndrome: State of the science. *J Cancer Surviv* 2009;3:21–42.
61. Hamilton JG, Lobel M, Moyer A. Emotional distress following genetic testing for hereditary breast and ovarian cancer: A meta-analytic review. *Health Psychol* 2009;28:510–518.
62. Reichelt JG, Møller P, Heimdal K, et al. Psychological and cancer-specific distress at 18 months post-testing in women with demonstrated BRCA1 mutations for hereditary breast/ovarian cancer. *Fam Cancer* 2008;7:245–254.
63. Lodder L, Frets PG, Trijsburg RW, et al. Psychological impact of receiving a BRCA1/BRCA2 test result. *Am J Med Genet* 2001;98:15–24.
64. Power TE, Robinson JW, Bridge P, et al. Distress and psychosocial needs of a heterogeneous high risk familial cancer population. *J Genet Couns* 2011; 20:249–269.
65. O'Neill SC, Rini C, Goldsmith RE, et al. Distress among women receiving uninformative BRCA1/2 results: 12-month outcomes. *Psychooncology* 2009;18:1088–1096.
66. Di Prospero LS, Seminsky M, Honeyford J, et al. Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: Findings from a focus group and a needs-assessment survey. *CMAJ* 2001;164:1005–1009.
67. Ertmanski S, Metcalfe K, Trempala J, et al. Identification of patients at high risk of psychological distress after BRCA1 genetic testing. *Genet Test Mol Biomarkers* 2009;13:325–330.
68. Roussi P, Sherman KA, Miller S, et al. Enhanced counselling for women undergoing BRCA1/2 testing: Impact on knowledge and psychological distress—results from a randomised clinical trial. *Psychol Health* 2010;25:401–415.
69. Shochat T, Dagan E. Sleep disturbances in asymptomatic BRCA1/2 mutation carriers: Women at high risk for breast-ovarian cancer. *J Sleep Res* 2010;19: 333–340.
70. Werner-Lin A. Formal and informal support needs of young women with BRCA mutations. *J Psychosoc Oncol* 2008;26:111–133.
71. Werner-Lin A. Beating the biological clock: The compressed family life cycle of young women with BRCA gene alterations. *Soc Work Health Care* 2008;47:416–437.
72. Metcalfe KA, Liede A, Hoodfar E, et al. An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling. *J Med Genet* 2000;37:866–874.
73. McKinnon W, Naud S, Ashikaga T, et al. Results of an intervention for individuals and families with BRCA mutations: a model for providing medical updates and psychosocial support following genetic testing. *J Genet Couns* 2007;16:433–456.
74. Lodder L, Frets PG, Trijsburg RW, et al. Men at risk of being a mutation carrier for hereditary breast/ovarian cancer: An exploration of attitudes and psychological functioning during genetic testing. *Eur J Hum Genet* 2001;9:492–500.
75. Sidransky D, Tokino T, Helzlsouer K, et al. Inherited p53 gene mutations in breast cancer. *Cancer Res* 1992;52:2984–2986.
76. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. *Science* 1990;250:1233–1238.
77. Birch JM, Hartley AL, Tricker KJ, et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. *Cancer Res* 1994;54:1298–1304.
78. Srivastava S, Zou ZQ, Pirolo K, et al. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. *Nature* 1990;348:747–749.
79. Varley JM, McGown G, Thorncraft M, et al. Germ-line mutations of TP53 in Li-Fraumeni families: An extended study of 39 families. *Cancer Res* 1997;57:3245–3252.
80. Li FP, Fraumeni JF Jr, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. *Cancer Res* 1988;48:5358–5362.
81. Gonzalez KD, Nollner KA, Buzin CH, et al. Beyond Li Fraumeni syndrome: Clinical characteristics of families with p53 germline mutations. *J Clin Oncol* 2009;27:1250–1256.
82. Nichols KE, Malkin D, Garber JE, et al. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. *Cancer Epidemiol Biomarkers Prev* 2001;10:83–87.
83. Hwang SJ, Lozano G, Amos CI, et al. Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. *Am J Hum Genet* 2003;72:975–983.
84. Kleihues P, Schäuble B, zur Hausen A, et al. Tumors associated with p53 germline mutations: a synopsis of 91 families. *Am J Pathol* 1997;150:1–13.
85. Olivier M, Goldgar DE, Sodha N, et al. Li-Fraumeni and related syndromes: Correlation between tumor type, family structure, and TP53 genotype. *Cancer Res* 2003;63:6643–6650.
86. Birch JM, Alston RD, McNally RJ, et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. *Oncogene* 2001;20: 4621–4628.
87. Strong LC, Williams WR, Tainsky MA. The Li-Fraumeni syndrome: From clinical epidemiology to molecular genetics. *Am J Epidemiol* 1992;135: 190–199.
88. Chompret A, Brugières L, Ronsin M, et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. *Br J Cancer* 2000;82:1932–1937.
89. Chompret A, Abel A, Stoppa-Lyonnet D, et al. Sensitivity and predictive value of criteria for p53 germline mutation screening. *J Med Genet* 2001;38: 43–47.
90. Varley JM, Evans DG, Birch JM. Li-Fraumeni syndrome—a molecular and clinical review. *Br J Cancer* 1997;76:1–14.
91. Frebourg T, Barbier N, Yan YX, et al. Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. *Am J Hum Genet* 1995;56:608–615.
92. Brugières L, Gardes M, Moutou C, et al. Screening for germ line p53 mutations in children with malignant tumors and a family history of cancer. *Cancer Res* 1993;53:452–455.
93. Le Bihan C, Moutou C, Brugières L, et al. ARCAD: A method for estimating age-dependent disease risk associated with mutation carrier status from family data. *Genet Epidemiol* 1995;12:13–25.
94. Wu CC, Shete S, Amos CI, et al. Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome. *Cancer Res* 2006;66: 8287–8292.
95. Hisada M, Garber JE, Fung CY, et al. Multiple primary cancers in families with Li-Fraumeni syndrome. *J Natl Cancer Inst* 1998;90:606–611.
96. Dorval M, Patenaude AF, Schneider KA, et al. Anticipated versus actual emotional reactions to disclosure of results of genetic tests for cancer susceptibility: findings from p53 and BRCA1 testing programs. *J Clin Oncol* 2000;18:2135–2142.
97. Peterson SK, Pentz ED, Marani SK, et al. Psychological functioning in persons considering genetic counseling and testing for Li-Fraumeni syndrome. *Psychooncology* 2008;17:783–789.
98. Oppenheim D, Brigieres L, Chompret A, et al. The psychological burden inflicted by multiple cancers in Li-Fraumeni families: Five case studies. *J Genet Couns* 2001;10:169–183.
99. Nelen MR, Kremer H, Konings IB, et al. Novel PTEN mutations in patients with Cowden disease: Absence of clear genotype-phenotype correlations. *Eur J Hum Genet* 1999;7:267–273.
100. PTEN hamartoma tumor syndrome (PHTS). 2011. <http://www.ncbi.nlm.nih.gov/books/NBK1488/>. Accessed April 23, 2012.
101. Zhou XP, Woodford-Richens K, Lehtonen R, et al. Germline mutations in BMP1A/ALK3 cause a subset of cases of juvenile polyposis syndrome and of Cowden and Bannayan-Riley-Ruvalcaba syndromes. *Am J Hum Genet* 2001;69:704–711.
102. Ni Y, Zbuk KM, Sadler T, et al. Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes. *Am J Hum Genet* 2008;83:261–268.
103. Eng C. Will the real Cowden syndrome please stand up: Revised diagnostic criteria. *J Med Genet* 2000;37:828–830.
104. Tan MH, Mester JL, Ngeow J, et al. Lifetime cancer risks in individuals with germline PTEN mutations. *Clin Cancer Res* 2012;18:400–407.
105. Pilarski R. Cowden syndrome: A critical review of the clinical literature. *J Genet Couns* 2009;18:13–27.
106. Conti S, Condò M, Posar A, et al. Phosphatase and tensin homolog (PTEN) gene mutations and autism: Literature review and a case report of a patient with Cowden syndrome, autistic disorder, and epilepsy. *J Child Neurol* 2012; 27:392–397.
107. Smith JR, Margusee E, Webb S, et al. Thyroid nodules and cancer in children with PTEN hamartoma tumor syndrome. *J Clin Endocrinol Metab* 2011;96:34–37.
108. Zbuk KM, Eng C. Hamartomatous polyposis syndromes. *Nat Clin Pract Gastroenterol Hepatol* 2007;4:492–502.
109. Kutscher AH, Zegarelli EV, Rankow RM, et al. Incidence of Peutz-Jeghers syndrome. *Am J Dig Dis* 1960;5:576–577.
110. Beggs AD, Latchford AR, Vasen HF, et al. Peutz-Jeghers syndrome: A systematic review and recommendations for management. *Cut* 2010;59:975–986.
111. Lim W, Olschwang S, Keller JJ, et al. Relative frequency and morphology of cancers in STK11 mutation carriers. *Gastroenterology* 2004;126: 1788–1794.
112. Hearle N, Schumacher V, Menko FH, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. *Clin Cancer Res* 2006;12:3209–3215.
113. Fitzgerald RC, Hardwick R, Hunstman D, et al. Hereditary diffuse gastric cancer: Updated consensus guidelines for clinical management and directions for future research. *J Med Genet*. 2010;47:436–444.
114. Kluij I, Sijmons RH, Hoogerbrugge N, et al. Familial gastric cancer: Guidelines for diagnosis, treatment and periodic surveillance. *Fam Cancer* 2012;11:363–369.
115. Howlander N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975–2008, National Cancer Institute. Bethesda, MD. [http://seer.cancer.gov/csr/1975\\_2008/](http://seer.cancer.gov/csr/1975_2008/), based on November 2010 SEER data submission, posted to the SEER web site, 2011. Accessed September 3, 2014.
116. Kaurah P, MacMillan A, Boyd N, et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. *JAMA* 2007;297:2360–2372.
117. Brooks-Wilson AR, Kaurah P, Suriano G, et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: Assessment of 42 new families and review of genetic screening criteria. *J Med Genet* 2004;41:508–517.
118. Pharoah PD, Guilford P, Caldas C, et al. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. *Gastroenterology* 2001;121:1348–1353.

119. Keller G, Vogelsang H, Becker I, et al. Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. *Am J Pathol* 1999;155:337–342.
120. Oliveira C, Bordin MC, Grehan N, et al. Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. *Hum Mutat* 2002;19:510–517.
121. Frebourg T, Oliveira C, Hochain P, et al. Cleft lip/palate and CDH1/E-cadherin mutations in families with hereditary diffuse gastric cancer. *J Med Genet* 2006;43:138–142.
122. Schrader KA, Masciari S, Boyd N, et al. Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers. *J Med Genet* 2011;48:64–68.
123. Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. *Proc Natl Acad Sci U S A* 2011;108:18032–18037.
124. Ripperger T, Gadzicki D, Meindl A, et al. Breast cancer susceptibility: Current knowledge and implications for genetic counselling. *Eur J Hum Genet* 2009;17:722–731.
125. Lalloo F, Evans DG. Familial breast cancer. *Clin Genet* 2012;82:105–114.
126. Shuen AY, Foulkes WD. Inherited mutations in breast cancer genes—risk and response. *J Mammary Gland Biol Neoplasia* 2011;16:3–15.
127. Weissman SM, Bellcross C, Bittner CC, et al. Genetic counseling considerations in the evaluation of families for Lynch syndrome—a review. *J Genet Couns* 2011;20:5–19.
128. Watson P, Vasen HF, Mecklin JP, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. *Int J Cancer* 2008;123:444–449.
129. Win AK, Young JP, Lindor NM, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. *J Clin Oncol* 2012;30:958–964.
130. Walsh MD, Buchanan DD, Cummings MC, et al. Lynch syndrome-associated breast cancers: Clinicopathologic characteristics of a case series from the colon cancer family registry. *Clin Cancer Res* 2010;16:2214–2224.
131. Buerki N, Gautier L, Kovac M, et al. Evidence for breast cancer as an integral part of Lynch syndrome. *Genes Chromosomes Cancer* 2012;51:83–91.
132. Lefevre JH, Colas C, Coulet F, et al. MYH biallelic mutation can inactivate the two genetic pathways of colorectal cancer by APC or MLH1 transversions. *Fam Cancer* 2010;9:589–594.
133. Sieber OM, Lipton L, Crabtree M, et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. *N Engl J Med* 2003;348:791–799.
134. Boparai KS, Dekker E, Van Eeden S, et al. Hyperplastic polyps and sessile serrated adenomas as a phenotypic expression of MYH-associated polyposis. *Gastroenterology* 2008;135:2014–2018.
135. Vogt S, Jones N, Christian D, et al. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. *Gastroenterology* 2009;137:1976–1985.e1–e10.
136. Nielsen M, Franken PF, Reinards TH, et al. Multiplicity in polyp count and extracolonic manifestations in 40 Dutch patients with MYH associated polyposis coli (MAP). *J Med Genet* 2005;42:e54.
137. Beiner ME, Zhang WW, Zhang S, et al. Mutations of the MYH gene do not substantially contribute to the risk of breast cancer. *Breast Cancer Res Treat* 2009;114:575–578.